DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT02170324

CompletedPhase 4

GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men

Lead sponsor

Xiang Guang-da

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

20

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI ≥30•Male

Primary endpoint

•Expression of brown adipose related genes in subcutaneous white adipose tissue

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02170324
Org study ID2014Wze091

Timeline

Milestones

Study first posted2014-06-23estimated
Last update posted2017-01-18estimated
Study start2014-06 (month precision)
Primary completion2015-07actual (month precision)
Study completion2015-07actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age20 Years
Maximum age30 Years
SexMale
Healthy volunteersNot accepted

Inclusion criteria

•Body mass index (BMI) > 30 kg/m2
•Men
•Age 20 - 30 years old

Exclusion criteria

•BMI < 30 kg/m2
•Diabetes
•Hypertension
•Use of medicines

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

The expression of brown adipose related genes in subcutaneous white adipose tissue

Time frame:3 months

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.